These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 33011724

  • 1. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
    Borchers L, Roider J, Klettner A.
    Ophthalmic Res; 2021; 64(3):369-388. PubMed ID: 33011724
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J, Randoll N, Lucius R, Caliebe A, Roider J, Klettner A.
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [Abstract] [Full Text] [Related]

  • 3. The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium.
    Dithmer M, Hattermann K, Pomarius P, Aboul Naga SH, Meyer T, Mentlein R, Roider J, Klettner A.
    Exp Eye Res; 2016 Apr; 145():187-205. PubMed ID: 26773870
    [Abstract] [Full Text] [Related]

  • 4. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.
    Vo TA, Abedi S, Schneider K, Chwa M, Kenney MC.
    Exp Eye Res; 2018 Dec; 177():112-116. PubMed ID: 30071215
    [Abstract] [Full Text] [Related]

  • 5. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
    Ranjbar M, Brinkmann MP, Zapf D, Miura Y, Rudolf M, Grisanti S.
    Cell Physiol Biochem; 2016 Dec; 38(2):737-47. PubMed ID: 26871551
    [Abstract] [Full Text] [Related]

  • 6. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB, Rho CR, Shin JA, Lyu J, Kang S.
    Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A, Recber M, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ, Chao YM, Liu NC, Chan JY.
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
    Malik D, Tarek M, Caceres del Carpio J, Ramirez C, Boyer D, Kenney MC, Kuppermann BD.
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intracellular pathways following uptake of bevacizumab in RPE cells.
    Aboul Naga SH, Dithmer M, Chitadze G, Kabelitz D, Lucius R, Roider J, Klettner A.
    Exp Eye Res; 2015 Feb; 131():29-41. PubMed ID: 25533679
    [Abstract] [Full Text] [Related]

  • 13. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M, Fernández-Robredo P, Hernández M, Bezunartea J, Reiter N, Recalde S, García-Layana A.
    Biochem Pharmacol; 2016 Mar 01; 103():129-39. PubMed ID: 26793998
    [Abstract] [Full Text] [Related]

  • 14. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
    Dinç E, Ayaz L, Kurt AH.
    J Ocul Pharmacol Ther; 2018 May 01; 34(4):346-353. PubMed ID: 29389239
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N, Terasaki H, Shirasawa M, Kawano H, Sonoda S, Yamaguchi M, Hashiguchi T, Hisatomi T, Ishibashi T, Sakamoto T.
    Retina; 2017 Jan 01; 37(1):179-190. PubMed ID: 28005721
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A, Sanguineti R, Traverso CE, Viviani GL, Nicolò M.
    Eur J Ophthalmol; 2016 Aug 04; 26(5):425-30. PubMed ID: 27079208
    [Abstract] [Full Text] [Related]

  • 20. Pro-inflammatory activation changes intracellular transport of bevacizumab in the retinal pigment epithelium in vitro.
    Hildebrandt J, Käckenmeister T, Winkelmann K, Dörschmann P, Roider J, Klettner A.
    Graefes Arch Clin Exp Ophthalmol; 2022 Mar 04; 260(3):857-872. PubMed ID: 34643794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.